New drug gemini tested for kidney disease safety
NCT ID NCT06863467
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 27 times
Summary
This early-stage study tested a single dose of an experimental drug called Gemini in 40 adults with moderate to severe chronic kidney disease (stages 3 and 4). The main goal was to check if Gemini is safe and tolerable compared to a placebo. Researchers also measured how the drug moves through the body and looked for signs it might affect inflammation or kidney function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Institute of Renal Research
Chula Vista, California, 91911, United States
-
California Institute of Renal Research
La Mesa, California, 92942, United States
-
Clinical Advance Center, PLLC
San Antonio, Texas, 78212, United States
Conditions
Explore the condition pages connected to this study.